ibandronic acid and Bone Loss, Perimenopausal
ibandronic acid has been researched along with Bone Loss, Perimenopausal in 184 studies
Research
Studies (184)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 9 (4.89) | 18.2507 |
2000's | 97 (52.72) | 29.6817 |
2010's | 62 (33.70) | 24.3611 |
2020's | 16 (8.70) | 2.80 |
Authors
Authors | Studies |
---|---|
Feng, D; Ke, L; Liu, J; Luo, F; Mori, T; Wan, Y; You, R; Yu, G; Zhang, Y | 1 |
Baek, KH; Kang, MI; Kim, J; Kim, KM; Lim, S; Min, YK | 1 |
Dong, S; Hu, Y; Ke, Z; Lv, M; Shen, J; Song, L; Wu, K; Xu, K; Yuan, Y | 1 |
Baim, S; Bedrose, S; Casagrande, A; Go, MT; Goel, M; Hanna, M; Husni, H; Li, D; Mahrous, P; Morkos, M | 1 |
Kobayakawa, T; Miyazaki, A; Nakamura, Y; Takahashi, J | 1 |
Bartsch, R; Borchert, J; Hadji, P; Kossack, N; O'Kelly, J; Pignot, M | 1 |
Ehrenstein, V; Kafatos, G; Neasham, D; O'Kelly, J; Pedersen, AB; Risbo, N | 1 |
Alves, C; Batel-Marques, F; Donato, A; Mendes, D; Oliveira, T; Penedones, A | 1 |
Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T | 1 |
Bonel, H; Everts-Graber, J; Gahl, B; Häuselmann, H; Lehmann, D; Lehmann, T; Reichenbach, S; Studer, U; Ziswiler, HR | 1 |
Bao, X; Gao, L; Li, Y; Liu, C; Tian, Y; Wang, K | 1 |
Chen, LH; Ma, WJ; Wang, WY; You, RX | 1 |
Bastounis, A; Bishop, S; Corp, N; Gittoes, N; Griffin, J; Langley, T; Leonardi-Bee, J; Narayanasamy, MJ; Paskins, Z; Sahota, O | 1 |
Chiu, WY; Lin, CJ; Reginster, JY; Tsai, KS; Yang, WS | 1 |
Eastell, R; Fontalis, A | 1 |
Betsch, M; Colarossi, G; Eschweiler, J; Maffulli, N; Migliorini, F; Tingart, M | 1 |
Baek, GH; Gong, HS; Noh, JH; Roh, YH | 1 |
Boyanov, M; Intorcia, M; Petkova, R; Petranova, T; Psachoulia, E; Shinkov, A | 1 |
Bradburn, M; Eastell, R; Gossiel, F; McCloskey, EV; Naylor, KE; Paggiosi, MA; Peel, NFA; Walsh, JS | 1 |
Lee, DR; Lee, J | 1 |
Hongo, M; Horikawa, A; Kasukawa, Y; Kodama, H; Miyakoshi, N; Shimada, Y | 1 |
Brzeziańska, E; Cegłowska, A; Liberski, PP; Rieske, P; Sewerynek, E; Stêpień-Kłos, W; Stuss, M | 1 |
Black, DM; Burghardt, AJ; Majumdar, S; Palermo, L; Schafer, AL; Sellmeyer, DE; Shoback, DM | 1 |
Cerdá, D; Gifre, L; Guañabens, N; Monegal, A; Muxí, Á; Parés, A; Peris, P | 1 |
Aleksandrova, EN; Alekseeva, LI; Demin, NV; Sharapova, EP; Smirnov, AV; Taskina, EA; Zaitseva, EM | 1 |
Amling, M; Felsenberg, D; Hadji, P; Hofbauer, LC; Kandenwein, JA; Kurth, A | 1 |
Barr, C; Day, BM; Felsenberg, D; Harris, S; Masanauskaite, D; Miller, PD; Recker, RR; Reginster, J; Silverman, S | 1 |
Caffarelli, C; Franci, BM; Gonnelli, S; Lucani, B; Nuti, R; Pondrelli, C; Tanzilli, L | 1 |
Hviid, A; Pasternak, B; Svanström, H | 1 |
Bolognese, MA; Bone, HG; Bonnick, S; Brown, JP; Dakin, P; Ferreira, I; Hall, J; Ho, PR; Recknor, C; Roux, C; van den Bergh, JP; Wagman, RB | 1 |
Günther, B; Hans, D; Lippuner, K; Perrelet, R; Popp, AW; Senn, C | 1 |
Fadda, V; Maratea, D; Marinai, C; Messori, A; Trippoli, S | 1 |
Eastell, R; McCloskey, E; Paggiosi, MA; Peel, N; Walsh, JS | 1 |
Alam, SS; Baig, M; Tariq, S | 1 |
Hagino, H; Hashimoto, J; Matsunaga, M; Nakamura, T; Tobinai, M; Yoshida, S | 1 |
Hashimoto, J; Iida, S; Kawanishi, T; Nakai, K; Tobinai, M | 1 |
Fuksa, L; Horak, P; Ladova, K; Matoulkova, P; Palicka, V; Stepan, J; Touskova, T; Vytrisalova, M | 1 |
Agodoa, I; Bonnick, S; Brown, JP; Ferreira, I; Ho, PR; Palacios, S; Van den Bergh, JP | 1 |
Joa, KL; Jung, HY; Kim, CH; Kim, HS; Kim, MO; Kim, YJ; Kwon, SY | 1 |
Gambhir, JK; Goel, N; Rajaram, S; Rathi, V; Singh, N; Srividhya, NB | 1 |
Eastell, R; Gossiel, F; Jacques, RM; McCloskey, EV; Naylor, KE; Paggiosi, M; Peel, NF; Walsh, JS | 1 |
Buondonno, I; D'Amelio, P; D'Amico, L; Fornelli, G; Isaia, GC; Lucchiari, M; Marchetti, M; Roato, I; Sassi, F; Spertino, E | 1 |
Di Bonito, M; Ferretti, V; Giampà, E; Nuvoli, G; Paoletti, F; Piazzini, M; Ranieri, M; Tuveri, MA; Vinicola, V | 1 |
Adami, S; Gatti, D; Rossini, M; Viapiana, O | 2 |
Jędrzejczyk, S; Król, I; Sewerynek, E; Stępień-Kłos, W; Stuss, M | 1 |
Dohke, T; Iba, K; Kanaya, K; Sasaki, K; Takada, J; Wada, H; Yamashita, T; Yoshizaki, T | 1 |
Harris, ST; Insinga, R; Lewiecki, EM; Modi, A; Sajjan, S; Weaver, J | 1 |
Jiang, LA; Leder, BZ; Lee, H; Tsai, JN | 1 |
Buffat, H; Curkovic, I; Lippuner, K; Popp, AW; Popp, PF; Senn, C; Senn, R | 1 |
Bruyère, O; Neuprez, A; Reginster, JY | 1 |
Kastelan, D; Korsic, M; Vlak, T | 1 |
Adachi, JD; Adami, S; Cooper, C; Cranney, A; Delmas, PD; Miller, PD; Papapoulos, S; Reginster, JY; Sambrook, PN; Silverman, S; Siris, E; Wells, GA; Yetisir, E | 1 |
Burkiewicz, JS; Fit, KE; Griffin, BL; Meyer, CM | 1 |
Burge, RT; Lindsay, R; Marshall, DA; Tosteson, AN | 1 |
Davies, RY; Engelke, K; Fitzpatrick, LA; Fuerst, T; Genant, HK; Keaveny, TM; Kivitz, A; Kopperdahl, DL; Lewiecki, EM | 1 |
Body, JJ | 1 |
Bolognese, MA; McClung, MR; Miller, PD; Recker, RR; Sedarati, F | 1 |
Altabas, V; Crncevic Orlic, Z; Kastelan, D; Kolak, Z; Korsic, M; Lozo, P; Milas Ahic, J; Miskic, B; Stamenkovic, D; Vlak, T | 1 |
Emkey, RD | 1 |
Frampton, JE; Perry, CM | 1 |
Binkley, N; Dasic, G; Kohles, JD; Santiago, N; Silverman, SL; Simonelli, C; Sunyecz, JA | 1 |
Bilezikian, JP | 1 |
Lakatos, P | 1 |
Bachmann, GA; Binkley, N; Derman, RJ; Greenwald, M; Kohles, JD; Martens, MG; Silverman, SL | 1 |
Bolognese, M; Borges, JL; Cosman, F; Delmas, PD; Emkey, R; Epstein, S; Neate, C; Ragi-Eis, S; Recknor, C; Sedarati, F; Zerbini, CA | 1 |
Cotté, FE; Fardellone, P; Gaudin, AF; Mercier, F; Roux, C | 1 |
Bachmann, G; Bonnick, SL; Civitelli, R; Kohles, JD; Martens, M; Silverman, S; Tanner, SB | 1 |
Amling, M; Kurth, A | 1 |
Abelson, A; Gold, DT; Lange, JL; Ringe, JD; Thomas, T | 1 |
Byun, DW; Choi, WH; Chung, DJ; Chung, HY; Chung, YS; Kang, MI; Kim, GS; Kim, YK; Kwon, NH; Lee, IK; Lee, YS; Lim, SK; Min, YK; Park, IH; Park, JH; Shin, CS; Shong, MH; Yoon, HK | 1 |
Babbitt, A; Derman, R; Kohles, JD | 1 |
Li, M; Liu, DG; Liu, JL; Meng, XW; Xia, WB; Xing, XP; Zhang, ZL | 1 |
Bonvoisin, B; Czerwinski, E; Felsenberg, D; Langdahl, B; Masanauskaite, D; Recker, RR; Rowell, L; Ste-Marie, LG | 1 |
Hommann, M; Kaemmerer, D; Lehmann, G; Settmacher, U; Wolf, G | 1 |
Dasic, G; Davies, RY; Engelke, K; Fuerst, T; Genant, HK | 1 |
Cooper, C; Hartl, F; Lewiecki, EM; Mehta, D; Papapoulos, SE; Thompson, E | 1 |
Adam, JM; Albert, A; Cañete, A; de la Rosa, M; Gamilla, Z; Hsu, HC; Kung, AW; Lan, JL; Leerapan, T; Lin, HY; Lin, RM; Luevitoonvechkij, S; Navarra, S; Ngarmukos, S; Rachman, IA; Roeshadi, D; Rojanasthien, S; Songpatanasilp, T; Soong, YK; Soontrapa, S; Torralba, T; Tsai, K; Tu, ST; Vanbelle, S; Yuktanandana, P | 1 |
Cole, R | 1 |
Glendenning, P; Inderjeeth, CA; Lee, S | 1 |
Adami, S; Delmas, PD; Huss, H; Miller, PD; Patel, KM; Recker, RR; Schimmer, RC | 1 |
Bakula, M; Car, D; Crncevic-Orlic, Z; Dusek, T; Dzubur, F; Gradiser, M; Grubisic, F; Jajic, Z; Kadojic, M; Kastelan, D; Korsic, M; Kuster, Z; Labar, L; Lozo, P; Mijic, S; Miskic, B; Nikolic, T; Pekez, M; Poljicanin, T; Radman, M; Radovic, E; Strizak-Ujevic, M; Tajsic, G; Vlak, T; Vugrinec, M | 1 |
Carranza-Lira, S; García-Hernández, P; Motta-Martínez, E | 1 |
Jones, G; Winzenberg, T | 1 |
Backa, T; Duraj, V; Rapushi, E; Roshi, E; Zoto, A | 1 |
Carter, D; Churchill, W; Clapp, M; Reddy, P; Slovik, D; Yeh, Y | 1 |
Dubourg, G; Giraudeau, B; Perrodeau, E; Ravaud, P; Rouanet, S; Roux, C | 1 |
Bhattacharyya, I; Bowers, LM; Cohen, DM; Fitzpatrick, SG; Green, JG; Hinkson, DW; Neuman, AN; Stavropoulos, MF | 1 |
Jonkanski, I; Mautalen, C; Miller, PD; Ragi-Eis, S; Ramirez, F | 1 |
Czerwinski, E; Kenwright, A; Lakatos, P; Lorenc, R; Masanauskaite, D; Miller, PD; Recker, RR; Reginster, JY; Riis, BJ; Stakkestad, JA | 1 |
Aljinović, J; Bakula, M; Car, D; Crnčević-Orlić, Z; Dušek, T; Džubur, F; Gradišer, M; Grubišić, F; Jajić, Z; Kadojić, M; Kaštelan, D; Koršić, M; Kuster, Z; Labar, L; Lozo, P; Mijić, S; Miškić, B; Nikolić, T; Pekez, M; Poljičanin, T; Radman, M; Radović, E; Strižak-Ujević, M; Tajšić, G; Vlak, T; Vugrinec, M | 1 |
Bianchi, G; Burdeska, A; Czerwinski, E; Felsenberg, D; Kenwright, A; Recker, RR | 1 |
Lee, YH; Song, GG | 1 |
Armbrecht, G; Beller, G; Bock, O; Börst, H; Degner, C; Felsenberg, D; Martus, P; Roth, HJ | 1 |
Bae, SJ; Kim, BJ; Kim, GS; Kim, HK; Koh, JM; Lee, SH; Lim, KH | 1 |
Criswell, DF; Dave, M | 1 |
Black, DM; Eastell, R; Hietpas, J; Palermo, L; Schafer, AL; Sellmeyer, DE; Shoback, DM | 1 |
Bala, Y; Boivin, G; Kohles, J; Recker, RR | 1 |
Yates, J | 1 |
Kraenzlin, CA; Kraenzlin, ME; Lardelli, P; Meier, C; Sieber, P | 1 |
Bauss, F; Schimmer, RC | 1 |
Christiansen, C; Mahoney, P; McClung, MR; Schimmer, RC; Tankó, LB | 1 |
Baumann, M; Christgau, S; Christiansen, C; Hoyle, N; Lehmann, HJ; Moelgaard, A; Mouritzen, U; Qvist, P; Tankó, LB; Warming, L; Wieczorek, L | 1 |
Papapoulos, SE | 1 |
Burdeska, A; Christiansen, C; Czerwiński, E; Felsenberg, D; Hughes, C; Jonkanski, I; Tankó, LB | 1 |
Benevolenskaya, LI; Burdeska, A; Jonkanski, I; Mahoney, P; Nordby, A; Oefjord, E; Skag, A; Stakkestad, JA; Stepan, JJ | 1 |
Bianchi, G; Cooper, C; Emkey, RD; Hawker, G; McDonald, RH; Schimmer, RC; Wilson, K | 1 |
Adami, S; Crepaldi, G; Filipponi, P; Sartori, L | 1 |
Bonvoisin, B; Chesnut, CH; Hughes, C; Mahoney, P; Meunier, PJ; Recker, RR; Schimmer, RC; Weinstein, RS | 1 |
Burdeska, A; Cauley, JA; Chesnut, CH; Ensrud, KE; McClung, MR; Mills, T; Recker, R; Wasnich, RD | 1 |
Kuwahara, T; Suzuki, M; Tanaka, Y; Yamada, T | 1 |
Landais, P; Maravic, M | 1 |
Alexandersen, P; Bagger, YZ; Christiansen, C; Qin, G; Tankó, LB | 1 |
Chesnut, CH; Christiansen, C; Delmas, PD; Felsenberg, D; Gilbride, J; Hoiseth, A; Huss, H; Recker, R; Schimmer, RC; Skag, A; Stakkestad, JA | 1 |
Gieschke, R; Goggin, T; Jacqmin, P; Pillai, G; Schimmer, RC; Steimer, JL | 1 |
Goto, H; Inaba, M | 1 |
Chapurlat, RD | 1 |
Wallace, DJ | 1 |
Adami, S; Bolognese, MA; Bonvoisin, B; Civitelli, R; Cooper, C; Delmas, PD; Dumont, E; Felsenberg, D; Kendler, DL; McClung, MR; Miller, PD; Recker, RR; Reginster, JY; Stakkestad, JA | 1 |
Barrett, J; Bonvoisin, B; Dumont, E; Reginster, JY; Wilson, KM | 1 |
Bolognese, MA; Bonvoisin, B; Cooper, C; Delmas, PD; Felsenberg, D; Hughes, C; Kendler, DL; Lewiecki, EM; Luckey, M; Macovei, L; Mairon, N; McClung, MR; Miller, PD; Recker, RR; Reginster, JY; Stakkestad, JA | 1 |
McClung, M | 1 |
Rackoff, PJ; Sebba, A | 1 |
Armbrecht, G; Felsenberg, D; Miller, P; Papapoulos, SE; Schimmer, RC; Wilson, K | 1 |
Ettinger, MP; Felsenberg, D; Harris, ST; Hiltbrunner, V; Miller, PD; Schimmer, RC; Skag, A; Wasnich, R; Wilson, K | 1 |
Reginster, JY | 3 |
Chesnut, CH; Gass, ML; Hamdy, RC; Holick, MF; Leib, ES; Lewiecki, ME; Maricic, M; Watts, NB | 1 |
Adami, S; Bonvoisin, B; Christiansen, C; Cooper, C; Delmas, PD; Drezner, MK; Emkey, R; Felsenberg, D; Greenwald, M; Lakatos, P; Mairon, N; Miller, PD; Reginster, JY; Rowell, L; Silverman, SL; Stepan, JJ | 1 |
Beusterien, K; Devas, V; Emkey, R; Kivitz, A; Koltun, W; Masanauskaite, D; Seidman, L | 1 |
Delaney, MF | 1 |
Polk, B | 1 |
Neuprez, A; Rabenda, V; Reginster, JY | 1 |
Delmas, PD; Emkey, R; Epstein, S; Hiltbrunner, V; Schimmer, RC; Wilson, KM | 1 |
Reid, DM | 1 |
Dawson-Hughes, B; Gass, M | 1 |
Adami, S; Bolognese, M; Christiansen, C; Civitelli, R; Delmas, PD; Drezner, MK; Felsenberg, D; Hughes, C; Masanauskaite, D; Recker, RR; Reginster, JY; Reid, DM; Sambrook, P; Stakkestad, JA; Strugala, C; Ward, P | 1 |
Pyon, EY | 1 |
Brankin, E; Cooper, A; Drake, J | 1 |
Epstein, S; Friend, K; Zaidi, M | 1 |
Chesnut, CH | 1 |
Chapurlat, RD; Delmas, PD | 1 |
Croom, KF; Scott, LJ | 1 |
Langdahl, B; Mosekilde, L; Vestergaard, P | 1 |
Kessenich, CR | 1 |
Gieschke, R; Reginster, JY | 1 |
Cooper, A | 1 |
Gold, DT; Safi, W; Trinh, H | 1 |
Papapoulos, SE; Schimmer, RC | 1 |
Botsis, D; Christodoulakos, G; Lambrinoudaki, I | 1 |
Armamento-Villareal, R; Civitelli, R; Napoli, N | 1 |
Maricic, M | 1 |
Díaz-Curiel, M; Moro Alvarez, MJ | 1 |
McHorney, CA; Weiss, TW | 1 |
Civitelli, R; Emkey, R; Strampel, W | 1 |
Byrjalsen, I; Christiansen, C; Karsdal, MA; Leeming, DJ; Qvist, P | 1 |
Rizzoli, R | 1 |
Epstein, S; Miller, PD; Reginster, JY; Sedarati, F | 1 |
Blumentals, WA; Harris, ST; Miller, PD | 1 |
Chesnut, CH; Epstein, S; Harris, ST; Kohles, JD; Zaidi, M | 1 |
Barrett-Connor, E; Bourgeois, P; Devas, V; Fardellone, P; Hadji, P; Licata, A; Masanauskaite, D; Minne, H; Pfeifer, M | 1 |
Málek, Z | 1 |
Alva, D; Cesareo, R; Contini, S; De Rosa, B; Iozzino, M; Lauria, A; Mallardo, L; Napolitano, C; Orsini, A; Reda, G | 1 |
Lakatos, P; Lorenc, R; Neate, C; Reginster, JY; Sedarati, F; Stakkestad, JA | 1 |
Adami, S; Civitelli, R; Czerwinski, E; Delmas, PD; Eisman, JA; Felsenberg, D; Hughes, C; Mairon, N; Masanauskaite, D; Prince, R; Recker, RR; Recknor, C; Reginster, JY; Reid, DM; Zaidi, M | 1 |
Kastelan, D; Vlak, T | 1 |
Christiansen, C; Clemmesen, B; Ravn, P; Riis, BJ | 1 |
Schlosser, K; Scigalla, P | 1 |
Burckhardt, P | 1 |
Burckhardt, P; Huss, H; Juttmann, JR; Kriegbaum, H; Mulder, H; Schöter, KH; Thiébaud, D | 1 |
Browning, M; Chesnut, CH; Gaffney, EV; Schöter, KH; Ulrich, U | 1 |
Alexandersen, P; Bjarnason, NH; Christgau, S; Christiansen, C; Fledelius, C; Herling, C; Qvist, P; Ravn, P; Rosenquist, C | 1 |
Balfour, JA; Dooley, M | 1 |
Alexandersen, P; Møllgaard, A; Ravn, P | 1 |
Bagger, Y; Christiansen, C; Ise, J; Riis, BJ; von Stein, T | 1 |
Christiansen, C; Neugebauer, G; Ravn, P | 1 |
Ravn, P | 1 |
Reviews
61 review(s) available for ibandronic acid and Bone Loss, Perimenopausal
Article | Year |
---|---|
Pharmacological Therapies for Osteoporosis: A Bayesian Network Meta-Analysis.
Topics: Bone Density; Bone Density Conservation Agents; Female; Hip Fractures; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Spinal Fractures | 2022 |
Ibandronate in the Prevention of Vertebral and Nonvertebral Osteoporotic Fractures: A Systematic Review of Experimental and Observational Studies.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Observational Studies as Topic; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid | 2023 |
The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome | 2023 |
Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials.
Topics: Denosumab; Female; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Spinal Fractures; Teriparatide; Zoledronic Acid | 2023 |
The challenge of long-term adherence: The role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis; Osteoporosis, Postmenopausal | 2020 |
Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis.
Topics: Alendronate; Bayes Theorem; Bone Density; Bone Density Conservation Agents; Denosumab; Female; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis; Osteoporosis, Postmenopausal; Pharmaceutical Preparations | 2021 |
Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies.
Topics: Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Europe; Female; Follow-Up Studies; Humans; Ibandronic Acid; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Spinal Fractures; United States | 2014 |
Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bis
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Collagen Type I; Denosumab; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Femur Neck; Hip Joint; Humans; Ibandronic Acid; Injections, Subcutaneous; Lumbar Vertebrae; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Peptides; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors | 2014 |
Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Female; Humans; Ibandronic Acid; Incidence; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Therapeutic Equivalency | 2014 |
The use of bisphosphonates in women: when to use and when to stop.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Factors; Time Factors; Zoledronic Acid | 2015 |
Ibandronate in profile: drug characteristics and clinical efficacy.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal | 2008 |
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Proportional Hazards Models; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
[Update on treatment of postmenopausal osteoporosis].
Topics: Bone Resorption; Calcium; Diphosphonates; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Meta-Analysis as Topic; Osteoporosis, Postmenopausal; Patient Compliance; Zoledronic Acid | 2008 |
Quarterly intravenous ibandronate for postmenopausal osteoporosis.
Topics: Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Ibandronic Acid; Injections, Intravenous; Osteoporosis, Postmenopausal; Treatment Outcome | 2008 |
Ibandronate: a review of its use in the management of postmenopausal osteoporosis.
Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Injections, Intravenous; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic | 2008 |
Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2009 |
[Ibandronate in the treatment of postmenopausal osteoporosis].
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal | 2008 |
Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Medication Adherence; Osteoporosis, Postmenopausal | 2009 |
Ibandronate: a review of its vertebral and nonvertebral antifracture efficacy.
Topics: Bone Density; Bone Density Conservation Agents; Cervical Vertebrae; Diphosphonates; Humans; Ibandronic Acid; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Thoracic Vertebrae | 2009 |
Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials.
Topics: Aged; Atrial Fibrillation; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Risk Factors | 2010 |
Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Middle Aged; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Patient Compliance; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Treatment Outcome | 2011 |
Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials.
Topics: Administration, Oral; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Evidence-Based Medicine; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Patient Preference; Radiography; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2011 |
A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Spine | 2013 |
Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.
Topics: Administration, Oral; Biomarkers; Bone Density; Bone Resorption; Clinical Trials, Phase II as Topic; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Injections, Intravenous; Osteoporosis, Postmenopausal; Time Factors | 2003 |
Ibandronate: a potent new bisphosphonate in the management of postmenopausal osteoporosis.
Topics: Administration, Oral; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Osteoporosis, Postmenopausal | 2003 |
Injectable bisphosphonates in the treatment of postmenopausal osteoporosis.
Topics: Anti-Inflammatory Agents; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Pamidronate; Zoledronic Acid | 2003 |
[Ibandronate].
Topics: Animals; Bone Density; Bone Resorption; Clinical Trials, Phase III as Topic; Diphosphonates; Humans; Ibandronic Acid; Osteoclasts; Osteoporosis, Postmenopausal; Patient Compliance; Randomized Controlled Trials as Topic; Spinal Fractures | 2004 |
A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis.
Topics: Administration, Oral; Biomarkers; Bone Resorption; Clinical Trials as Topic; Collagen; Collagen Type I; Diphosphonates; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Humans; Ibandronic Acid; Infusions, Intravenous; Models, Biological; Osteoporosis, Postmenopausal; Peptides; Treatment Outcome | 2004 |
[Ibandronate as a new therapeutic agent for osteoporosis].
Topics: Administration, Oral; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Humans; Ibandronic Acid; Injections, Intravenous; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic | 2005 |
Rapid prevention of vertebral fractures associated with osteoporosis.
Topics: Aged; Alendronate; Calcitonin; Clinical Trials as Topic; Diphosphonates; Estrogens; Female; Glucocorticoids; Humans; Ibandronic Acid; Imidazoles; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Risk Factors; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2005 |
A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.
Topics: Administration, Oral; Animals; Bone Density; Bone Density Conservation Agents; Clinical Trials, Phase I as Topic; Diphosphonates; Dogs; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Randomized Controlled Trials as Topic; Rats; Spinal Fractures | 2006 |
Use of highly potent bisphosphonates in the treatment of osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Remodeling; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Prognosis; Randomized Controlled Trials as Topic; Risedronic Acid; Severity of Illness Index; Treatment Outcome | 2003 |
Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis.
Topics: Administration, Oral; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Risedronic Acid | 2005 |
Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis.
Topics: Administration, Oral; Animals; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Patient Compliance; Randomized Controlled Trials as Topic | 2005 |
Review of treatment modalities for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Combined Modality Therapy; Diet; Dietary Supplements; Diphosphonates; Etidronic Acid; Exercise; Female; Fish Oils; Hip Fractures; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Teriparatide; Vitamin D; Vitamin D Deficiency | 2005 |
Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Injections, Intravenous; Middle Aged; Osteoporosis, Postmenopausal | 2005 |
Strategies for the prevention and treatment of osteoporosis during early postmenopause.
Topics: Accidental Falls; Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Exercise; Female; Humans; Ibandronic Acid; Life Style; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Perimenopause; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators; Smoking; Vitamin D | 2006 |
Adherence, patient preference and dosing frequency: understanding the relationship.
Topics: Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Patient Compliance; Patient Satisfaction; Prospective Studies; Randomized Controlled Trials as Topic; Treatment Outcome | 2006 |
Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Fractures, Bone; Gastrointestinal Diseases; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Risedronic Acid | 2006 |
Once-monthly dosing: an effective step forward.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Pilot Projects; Placebos; Randomized Controlled Trials as Topic | 2006 |
Preventing osteoporosis-related fractures: an overview.
Topics: Absorptiometry, Photon; Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Calcitonin; Calcium, Dietary; Dietary Supplements; Diphosphonates; Etidronic Acid; Exercise; Female; Fractures, Bone; Humans; Ibandronic Acid; Motor Activity; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Risedronic Acid; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Teriparatide; United States; Vitamin D | 2006 |
Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
Topics: Aged; Bone Density Conservation Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal | 2006 |
Treating osteoporosis with bisphosphonates and addressing adherence: a review of oral ibandronate.
Topics: Administration, Oral; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal | 2006 |
Drug insight: Bisphosphonates for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Risedronic Acid | 2006 |
Intravenous ibandronate: in the treatment of osteoporosis.
Topics: Animals; Area Under Curve; Bone and Bones; Bone Density; Diphosphonates; Drug Administration Schedule; Female; Half-Life; Humans; Ibandronic Acid; Injections, Intravenous; Metabolic Clearance Rate; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Tissue Distribution | 2006 |
Fracture prevention in postmenopausal women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Hormone Replacement Therapy; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Pamidronate; Parathyroid Hormone; Risedronic Acid; Selective Estrogen Receptor Modulators; Vitamin D | 2006 |
Ibandronate (boniva) offers new options for osteoporosis.
Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Intestinal Absorption; Metabolic Clearance Rate; Osteoporosis, Postmenopausal; Patient Selection; Treatment Outcome; United States | 2006 |
[Ibandronate (Bonviva) in the treatment of postmenopausal osteoporosis].
Topics: Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Patient Compliance | 2006 |
Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Treatment Outcome | 2007 |
Bisphosphonates.
Topics: Alendronate; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2006 |
New and emerging treatments for osteoporosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Drug Administration Routes; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Patient Compliance; RANK Ligand; Zoledronic Acid | 2007 |
Pharmacological treatment of osteoporosis for people over 70.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Parathyroid Hormone; Risedronic Acid; Thiophenes; Vitamin D | 2007 |
Safety considerations with bisphosphonates for the treatment of osteoporosis.
Topics: Acute-Phase Reaction; Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Ibandronic Acid; Injections, Intravenous; Jaw Diseases; Osteonecrosis; Osteoporosis, Postmenopausal; Renal Insufficiency; Risedronic Acid | 2007 |
Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies.
Topics: Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Risk Factors; Time Factors | 2008 |
Progression of efficacy with ibandronate: a paradigm for the development of new bisphosphonates.
Topics: Administration, Oral; Animals; Bone Density; Bone Density Conservation Agents; Chemistry, Pharmaceutical; Clinical Trials as Topic; Diphosphonates; Drug Administration Schedule; Drug Design; Humans; Ibandronic Acid; Osteoporosis; Osteoporosis, Postmenopausal; Proportional Hazards Models; Time Factors | 2007 |
[The benefit from ibandronate in the treatment of postmenopausal osteoporosis].
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal | 2007 |
Evidence based medicine and effective interventions of pharmacological therapy for the prevention of osteoporotic fractures.
Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Clodronic Acid; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Risedronic Acid; Selective Estrogen Receptor Modulators; Teriparatide; Thiophenes; Vitamin D | 2007 |
[Does ibandronate (Bonviva) have an impact on non-vertebral fractures?].
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal | 2007 |
Ibandronate in oncology.
Topics: Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Neoplasms; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic | 1997 |
Ibandronate.
Topics: Animals; Bone Density; Bone Neoplasms; Bone Resorption; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Male; Neoplasms; Osteitis Deformans; Osteoporosis, Postmenopausal | 1999 |
Bisphosphonates for prevention of postmenopausal osteoporosis.
Topics: Alendronate; Biomarkers; Bone Density; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic | 2002 |
Trials
71 trial(s) available for ibandronic acid and Bone Loss, Perimenopausal
Article | Year |
---|---|
Efficacy of bisphosphonate therapy on postmenopausal osteoporotic women with and without diabetes: a prospective trial.
Topics: Bone Density; Bone Density Conservation Agents; Diabetes Mellitus, Type 2; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Prospective Studies; Treatment Outcome | 2022 |
Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study.
Topics: Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Denosumab; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Prospective Studies | 2022 |
Comparative adherence to weekly oral and quarterly intravenous bisphosphonates among patients with limited heath literacy who sustained distal radius fractures.
Topics: Administration, Intravenous; Administration, Oral; Alendronate; Bone Density Conservation Agents; Demography; Diphosphonates; Drug Administration Schedule; Female; Health Education; Humans; Ibandronic Acid; Injections, Intravenous; Medication Adherence; Middle Aged; Multivariate Analysis; Osteoporosis, Postmenopausal; Radius Fractures | 2018 |
Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Drug Administration Schedule; Female; Hip Joint; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Withholding Treatment | 2018 |
A prospective comparative study of intravenous alendronate and ibandronate for the treatment of osteoporosis.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Prospective Studies; Treatment Outcome | 2019 |
Assessment of OPG/RANK/RANKL gene expression levels in peripheral blood mononuclear cells (PBMC) after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Cholecalciferol; Combined Modality Therapy; Dietary Supplements; Diphosphonates; Female; Gene Expression Regulation; Humans; Ibandronic Acid; Leukocytes, Mononuclear; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Osteoprotegerin; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; RNA, Messenger; Thiophenes | 2013 |
Postmenopausal women treated with combination parathyroid hormone (1-84) and ibandronate demonstrate different microstructural changes at the radius vs. tibia: the PTH and Ibandronate Combination Study (PICS).
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Female; Finite Element Analysis; Humans; Ibandronic Acid; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Radius; Tibia; Tomography, X-Ray Computed; Weight-Bearing | 2013 |
Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Ibandronic Acid; Liver Cirrhosis, Biliary; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Treatment Outcome | 2013 |
The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Analgesics; Bone Density Conservation Agents; Diphosphonates; Drug Utilization; Female; Humans; Ibandronic Acid; Injections, Intravenous; Kaplan-Meier Estimate; Medication Adherence; Middle Aged; Motor Activity; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Treatment Outcome | 2014 |
Effects of intravenous zoledronate and ibandronate on carotid intima-media thickness, lipids and FGF-23 in postmenopausal osteoporotic women.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Carotid Intima-Media Thickness; Diphosphonates; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Ibandronic Acid; Imidazoles; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Zoledronic Acid | 2014 |
Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Hip Joint; Humans; Ibandronic Acid; Lower Extremity; Lumbar Vertebrae; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Upper Extremity | 2014 |
Increased bone mineral density with monthly intravenous ibandronate contributes to fracture risk reduction in patients with primary osteoporosis: three-year analysis of the MOVER study.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Injections, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid | 2014 |
Application of modeling and simulation to a long-term clinical trial: a direct comparison of simulated data and data actually observed in Japanese osteoporosis patients following 3-year ibandronate treatment.
Topics: Biomarkers, Pharmacological; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Collagen Type I; Computer Simulation; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Models, Biological; Osteoporosis, Postmenopausal; Peptides | 2015 |
Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.
Topics: Aged; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Drug Substitution; Etidronic Acid; Female; Humans; Ibandronic Acid; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Patient Satisfaction; Risedronic Acid; Treatment Outcome | 2015 |
Comparison of antiresorptive effect of hormone therapy and ibandronate in postmenopausal osteoporotic women by assessing type I collagen C-telopeptide levels.
Topics: Absorptiometry, Photon; Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Hormone Replacement Therapy; Humans; Ibandronic Acid; India; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Prospective Studies; Risk Assessment; Treatment Outcome | 2015 |
Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Premenopause; Reference Values; Risedronic Acid; Treatment Outcome | 2016 |
Treatment with intermittent PTH increases Wnt10b production by T cells in osteoporotic patients.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Calcium; Diphosphonates; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hyperparathyroidism, Primary; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Proto-Oncogene Proteins; RNA, Messenger; T-Lymphocytes; Vitamin D; Wnt Proteins | 2015 |
Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Teriparatide; Zoledronic Acid | 2017 |
Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Aged, 80 and over; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Finite Element Analysis; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Tomography, X-Ray Computed | 2009 |
Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.
Topics: Administration, Oral; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Treatment Outcome | 2009 |
Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Patient Satisfaction; Prospective Studies; Quality of Life; Surveys and Questionnaires; Time Factors | 2009 |
Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression.
Topics: Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Collagen Type I; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Prospective Studies; Treatment Outcome | 2009 |
Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Gastroesophageal Reflux; Heartburn; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Patient Satisfaction; Risedronic Acid | 2009 |
Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Treatment Outcome | 2009 |
Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.
Topics: Aged; Bone and Bones; Bone Density Conservation Agents; Collagen Type I; Cross-Over Studies; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandronic Acid; Korea; Middle Aged; Osteoporosis, Postmenopausal; Patient Preference; Peptides; Prospective Studies; Risedronic Acid | 2009 |
Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study.
Topics: Aged; Alkaline Phosphatase; Biomarkers; Body Height; Bone Density; Bone Density Conservation Agents; Bone Resorption; China; Collagen Type I; Diphosphonates; Female; Femur; Femur Neck; Humans; Ibandronic Acid; Infusions, Intravenous; Lumbar Vertebrae; Middle Aged; Muscular Diseases; Osteoporosis, Postmenopausal; Pain; Peptides; Time Factors | 2010 |
Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study.
Topics: Aged; Bone and Bones; Bone Density; Bone Remodeling; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Injections, Intravenous; Middle Aged; Osteoporosis, Postmenopausal | 2010 |
Treatment of osteoporosis after liver transplantation with ibandronate.
Topics: Absorptiometry, Photon; Adult; Aged; Alkaline Phosphatase; Bone Density; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Liver Transplantation; Male; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone | 2010 |
Regional distribution of spine and hip QCT BMD responses after one year of once-monthly ibandronate in postmenopausal osteoporosis.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Femur Neck; Hip Joint; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Spine | 2010 |
Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women.
Topics: Administration, Oral; Aged; Aged, 80 and over; Asian People; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Patient Satisfaction | 2009 |
Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Hip Joint; Humans; Ibandronic Acid; Injections, Intravenous; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Radiography; Spinal Fractures | 2010 |
Health-related quality of life among patients with postmenopausal osteoporosis treated with weekly and monthly bisphosphonates.
Topics: Aged; Bone Density Conservation Agents; Chi-Square Distribution; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies; Quality of Life; Surveys and Questionnaires | 2010 |
[Monthly ibandronate attachment to Mexican and Chilean women with osteoporosis, with or without a biofeedback strategy].
Topics: Administration, Oral; Aged; Biofeedback, Psychology; Biomarkers; Bone Density Conservation Agents; Calcium; Chile; Collagen Type I; Diphosphonates; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Ibandronic Acid; Mexico; Middle Aged; Osteoporosis, Postmenopausal; Pain; Patient Compliance; Patient Satisfaction; Peptides; Prospective Studies; Vitamin D | 2010 |
Monitoring of bone turnover markers does not improve persistence with ibandronate treatment.
Topics: Biomarkers; Bone Density Conservation Agents; Bone Resorption; Collagen Type I; Diphosphonates; Drug Monitoring; Female; Humans; Ibandronic Acid; Male; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies | 2012 |
Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease--the DIVINE study.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Endpoint Determination; Female; Glomerular Filtration Rate; Humans; Ibandronic Acid; Injections, Intravenous; Kidney Diseases; Kidney Function Tests; Osteoporosis, Postmenopausal; Risk Factors | 2011 |
Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Double-Blind Method; Female; Femur; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Treatment Outcome | 2012 |
Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Longitudinal Studies; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Treatment Outcome | 2012 |
Impact of oral ibandronate 150 mg once monthly on bone structure and density in post-menopausal osteoporosis or osteopenia derived from in vivo μCT.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; X-Ray Microtomography | 2012 |
Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Pilot Projects; Treatment Outcome | 2012 |
Oral ibandronate in postmenopausal osteoporotic women alters micromechanical properties independently of changes in mineralization.
Topics: Administration, Oral; Aged; Biopsy; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Regression Analysis; Reproducibility of Results; Treatment Outcome | 2013 |
The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Aged, 80 and over; Bone Density; Collagen; Collagen Type I; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Female; Humans; Ibandronic Acid; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Peptides; Time Factors | 2003 |
Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens.
Topics: Administration, Oral; Aged; Analysis of Variance; Biomarkers; Bone Regeneration; Bone Remodeling; Bone Resorption; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Osteogenesis; Osteoporosis, Postmenopausal | 2003 |
Oral weekly ibandronate prevents bone loss in postmenopausal women.
Topics: Administration, Oral; Alkaline Phosphatase; Analysis of Variance; Bone Density; Bone Resorption; Collagen Type I; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Ibandronic Acid; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Time Factors | 2003 |
Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.
Topics: Alkaline Phosphatase; Biomarkers; Bone Density; Collagen; Collagen Type I; Czech Republic; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Injections, Intravenous; Lumbar Vertebrae; Middle Aged; Norway; Osteocalcin; Osteoporosis, Postmenopausal; Parathyroid Hormone; Peptides; Russia; Statistics, Nonparametric | 2003 |
Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Biomarkers; Bone Density; Diphosphonates; Double-Blind Method; Female; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Treatment Outcome | 2003 |
Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study.
Topics: Aged; Biopsy; Bone Remodeling; Diphosphonates; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Ibandronic Acid; Ilium; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic | 2004 |
Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
Topics: Aged; Bone and Bones; Bone Density; Canada; Collagen; Collagen Type I; Data Interpretation, Statistical; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Femur; Femur Neck; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Parathyroid Hormone; Patient Compliance; Patient Selection; Pelvic Bones; Peptides; Time Factors; Treatment Outcome; United States | 2004 |
Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aortic Diseases; Bone Density; Bone Resorption; Calcinosis; Diphosphonates; Disease Progression; Double-Blind Method; Female; Humans; Ibandronic Acid; Injections, Intravenous; Long-Term Care; Middle Aged; Osteoporosis, Postmenopausal | 2005 |
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
Topics: Aged; Body Height; Bone and Bones; Bone Density; Diphosphonates; Double-Blind Method; Female; Femur; Fractures, Bone; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Patient Selection; Pelvic Bones; Prospective Studies; Risk Factors; Spinal Fractures; Treatment Outcome | 2004 |
Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Area Under Curve; Bone Remodeling; Bone Resorption; Collagen; Collagen Type I; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Feasibility Studies; Female; Gastrointestinal Diseases; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Peptides | 2005 |
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Bone Density; Collagen; Collagen Type I; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Risk Factors; Spinal Fractures; Spine; Treatment Outcome | 2005 |
Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Europe; Female; Humans; Ibandronic Acid; Incidence; Internationality; Lumbar Vertebrae; Middle Aged; North America; Osteoporosis, Postmenopausal; Risk; Severity of Illness Index; Spinal Fractures; Time Factors | 2005 |
Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Upper Gastrointestinal Tract | 2005 |
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Femur; Hip Joint; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Treatment Outcome | 2006 |
Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO).
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Cross-Over Studies; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Patient Satisfaction; Prospective Studies | 2005 |
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium; Collagen Type I; Diphosphonates; Double-Blind Method; Female; Humans; Ibandronic Acid; Injections, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Vitamin D | 2006 |
Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Social Support; Treatment Outcome | 2006 |
Modeling of serum C-telopeptide levels with daily and monthly oral ibandronate in humans.
Topics: Biomarkers; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Monitoring, Physiologic; Osteoporosis, Postmenopausal; Peptides | 2006 |
Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Collagen; Collagen Type I; Diphosphonates; Double-Blind Method; Estrogen Replacement Therapy; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Raloxifene Hydrochloride | 2008 |
Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Algorithms; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Treatment Outcome | 2008 |
Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cross-Over Studies; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Patient Satisfaction; Prospective Studies; Treatment Outcome | 2008 |
Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension.
Topics: Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Longitudinal Studies; Osteoporosis, Postmenopausal | 2008 |
Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.
Topics: Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal | 2008 |
The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Analysis of Variance; Biomarkers; Body Height; Body Weight; Bone Density; Bone Resorption; Calcium, Dietary; Collagen; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Femur; Forearm; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Treatment Outcome | 1996 |
Biochemical markers as surrogates in clinical trials in patients with metastatic bone disease and osteoporosis.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone and Bones; Bone Resorption; Calcitriol; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Ibandronic Acid; Injections, Intravenous; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Parathyroid Hormone; Placebos; Procollagen | 1997 |
Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Bone Density; Bone Resorption; Diphosphonates; Double-Blind Method; Female; Humans; Ibandronic Acid; Injections, Intravenous; Osteoporosis, Postmenopausal | 1997 |
Implementation of an osteoporosis research program with a mobile dual-energy X-ray absorptiometry unit: the Montana/Wyoming experience.
Topics: Absorptiometry, Photon; Aged; Clinical Trials as Topic; Diphosphonates; Equipment Design; Feasibility Studies; Female; Humans; Ibandronic Acid; Male; Middle Aged; Mobile Health Units; Osteoporosis, Postmenopausal; Patient Selection; Program Evaluation; Rural Population | 1997 |
Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides.
Topics: Aged; Biomarkers; Bone Density; Bone Resorption; Collagen; Collagen Type I; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Estrogen Replacement Therapy; Female; Humans; Ibandronic Acid; Middle Aged; Norpregnenes; Osteoporosis, Postmenopausal; Peptides; Sensitivity and Specificity | 1998 |
Bone densitometry: a new, highly responsive region of interest in the distal forearm to monitor the effect of osteoporosis treatment.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Analysis of Variance; Bone Resorption; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Estrogen Replacement Therapy; Female; Humans; Ibandronic Acid; Image Processing, Computer-Assisted; Linear Models; Male; Middle Aged; Osteoporosis, Postmenopausal; Radius; Sensitivity and Specificity; Ulna | 1999 |
Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Biomarkers; Bone Density; Bone Resorption; Consumer Product Safety; Cross-Over Studies; Diphosphonates; Drug Administration Schedule; Drug Tolerance; Female; Hip; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal | 2001 |
Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis.
Topics: Aged; Biomarkers; Bone Density; Bone Remodeling; Collagen; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Peptides | 2002 |
Other Studies
52 other study(ies) available for ibandronic acid and Bone Loss, Perimenopausal
Article | Year |
---|---|
Which injected antiosteoporotic medication is worth paying for? A cost-effectiveness analysis of teriparatide, zoledronate, ibandronate, and denosumab for postmenopausal osteoporotic women in China.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; China; Cost-Benefit Analysis; Denosumab; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Postmenopause; Teriparatide; Zoledronic Acid | 2021 |
Patterns of Osteoporosis Medications Selection After Drug Holiday or Continued Therapy: A Real-World Experience.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Retrospective Studies; Teriparatide; United States; Zoledronic Acid | 2022 |
Real-world effectiveness of osteoporosis treatments in Germany.
Topics: Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Female; Fractures, Bone; Germany; Humans; Ibandronic Acid; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Zoledronic Acid | 2022 |
Utilization patterns and factors associated with persistence of new users of anti-osteoporosis treatment in Denmark: a population-based cohort study.
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Denmark; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Risedronic Acid | 2023 |
Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Female; Hip Fractures; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Registries; Spinal Fractures; Zoledronic Acid | 2023 |
Denosumab Improves Glycaemic Parameters in Postmenopausal Osteoporosis Patients with Combined Type 2 Diabetes Mellitus.
Topics: Denosumab; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Glucose; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Transcription Factors | 2023 |
Clinicians' views of prescribing oral and intravenous bisphosphonates for osteoporosis: a qualitative study.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis; Osteoporosis, Postmenopausal; Zoledronic Acid | 2023 |
Racial difference in bioavailability of oral ibandronate between Caucasian and Taiwanese postmenopausal women.
Topics: Administration, Oral; Aged; Asian People; Biological Availability; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Race Factors; White People | 2020 |
Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates.
Topics: Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Bulgaria; Denosumab; Diphosphonates; Female; Femur Neck; Fractures, Bone; Humans; Ibandronic Acid; Lumbar Vertebrae; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Retrospective Studies | 2017 |
Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Databases, Factual; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Republic of Korea; Retrospective Studies; Risedronic Acid | 2019 |
[Evaluation of the efficacy and tolerance of ibandronic acid in patients with osteoarthrosis in the knee joints concurrent with osteoporosis: a pilot study].
Topics: Aged; Bone Density Conservation Agents; Bone Resorption; Cartilage; Diphosphonates; Disability Evaluation; Female; Humans; Ibandronic Acid; Locomotion; Middle Aged; Osteoarthritis, Knee; Osteoporosis, Postmenopausal; Pain; Pain Measurement; Pilot Projects; Severity of Illness Index | 2013 |
Use of strontium ranelate and risk of acute coronary syndrome: cohort study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denmark; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Proportional Hazards Models; Risedronic Acid; Thiophenes | 2014 |
Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study.
Topics: Absorptiometry, Photon; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Evaluation; Female; Humans; Ibandronic Acid; Injections, Intravenous; Injections, Subcutaneous; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Retrospective Studies; Teriparatide; Treatment Outcome | 2014 |
Effect of ibandronate therapy on serum homocysteine and leptin in postmenopausal osteoporotic females.
Topics: Bone Density; Bone Density Conservation Agents; Calcaneus; Case-Control Studies; Densitometry; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Female; Homocysteine; Humans; Ibandronic Acid; Leptin; Middle Aged; Osteoporosis, Postmenopausal; Treatment Outcome; Ultrasonography | 2015 |
Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Density Conservation Agents; Cross-Sectional Studies; Diphosphonates; Drug Administration Schedule; Female; Health Care Surveys; Health Knowledge, Attitudes, Practice; Humans; Ibandronic Acid; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Surveys and Questionnaires | 2015 |
Successful conservative treatment: multiple atypical fractures in osteoporotic patients after bisphosphate medication: a unique case report.
Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Femur; Fractures, Bone; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal | 2015 |
Results of a national multicentric study on compliance to treatment with various disphosphonate formulations in patients with postmenopausal osteoporosis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Retrospective Studies; Risedronic Acid | 2015 |
Assessment of OPG, RANKL, bone turnover markers serum levels and BMD after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Bone Remodeling; Diphosphonates; Drug Therapy, Combination; Female; Humans; Ibandronic Acid; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Osteoprotegerin; RANK Ligand; Thiophenes | 2016 |
Combined use of ibandronate and eldecalcitol in postmenopausal Japanese women with osteoporosis.
Topics: Absorptiometry, Photon; Aged; Asian People; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Femur; Humans; Ibandronic Acid; Japan; Middle Aged; Osteoporosis, Postmenopausal; Vitamin D | 2016 |
Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Databases, Factual; Denosumab; Diphosphonates; Drug Utilization; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Kaplan-Meier Estimate; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Retrospective Studies; Teriparatide; United States; Zoledronic Acid | 2017 |
Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate.
Topics: Acute-Phase Reaction; Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies; Risk Factors; Severity of Illness Index; Zoledronic Acid | 2017 |
Ibandronate: is there an effect on nonvertebral fractures?
Topics: Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Ibandronic Acid; Meta-Analysis as Topic; Osteoporosis, Postmenopausal | 2008 |
Acute phase reaction with intravenous ibandronate.
Topics: Acute-Phase Reaction; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Injections, Intravenous; Middle Aged; Osteoporosis, Postmenopausal | 2008 |
Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Budgets; Cost-Benefit Analysis; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Health Care Costs; Humans; Ibandronic Acid; Markov Chains; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Risedronic Acid; Risk Assessment; Risk Factors; United States | 2008 |
Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Drug Prescriptions; Epidemiologic Methods; Female; France; Humans; Ibandronic Acid; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures | 2010 |
Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases, Metabolic; Combined Modality Therapy; Diphosphonates; Drug Administration Schedule; Drug Substitution; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Patient Satisfaction; Prospective Studies; Surveys and Questionnaires | 2009 |
Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
Topics: Age Factors; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Epidemiologic Methods; Etidronic Acid; Female; Hip Fractures; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid; United States | 2010 |
Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Gastrointestinal Agents; Gastrointestinal Tract; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Surveys and Questionnaires | 2009 |
Postmenopausal osteoporosis: another approach to management.
Topics: Absorptiometry, Photon; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Medication Adherence; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Risk Assessment; Secondary Prevention; Zoledronic Acid | 2010 |
When do bisphosphonates make the most sense?
Topics: Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; United States; Women's Health | 2011 |
The efficiency of Bonviva (Ibadronate) in women with pre-post menopause.
Topics: Absorptiometry, Photon; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal | 2010 |
Intravenous bisphosphonates for post-menopausal osteoporosis: adherence to a network guideline.
Topics: 25-Hydroxyvitamin D 2; Aged; Bone Density Conservation Agents; Calcifediol; Calcium; Consensus; Diphosphonates; Drug Resistance; Electronic Health Records; Evidence-Based Medicine; Female; Guideline Adherence; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Longitudinal Studies; Middle Aged; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Zoledronic Acid | 2011 |
Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Mandibular Diseases; Maxillary Diseases; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Tooth Extraction; Tooth Socket; Zoledronic Acid | 2012 |
Monthly or weekly bisphosphonate? Evaluation of satisfaction in patients with postmenopausal osteoporosis using OPSAT-Q questionnaire during the BOOSTER study in Croatia.
Topics: Aged; Bone Density Conservation Agents; Croatia; Diphosphonates; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Patient Satisfaction; Prospective Studies; Quality of Life; Surveys and Questionnaires | 2011 |
Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Alendronate; Asian People; Bone Density; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Injections, Intravenous; Longitudinal Studies; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Postmenopause; Retrospective Studies; Risedronic Acid | 2012 |
Question: In postmenopausal women with osteoporosis is once monthly oral ibandronate (150 mg) therapy preferred to once weekly oral bisphosphonate therapy.
Topics: Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Patient Preference; Randomized Controlled Trials as Topic | 2012 |
Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
Topics: Acute-Phase Reaction; Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Imidazoles; Incidence; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Retrospective Studies; Zoledronic Acid | 2013 |
Injectable drug dampens bone loss.
Topics: Bone Density; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal | 2003 |
Ibandronate and prevention of postmenopausal osteoporosis.
Topics: Bone Density; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal | 2004 |
Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis.
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2005 |
[Monthly tablet].
Topics: Aged; Clinical Trials as Topic; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Europe; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance | 2005 |
Ibandronate (Boniva): a new oral bisphosphonate.
Topics: Administration, Oral; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal | 2005 |
[Postmenopausal osteoporosis].
Topics: Adult; Aged; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
[Ibandronate once a month].
Topics: Bone Density Conservation Agents; Delayed-Action Preparations; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal | 2006 |
[Monthly tablet in postmenopausal osteoporosis].
Topics: Administration, Oral; Bone Density; Bone Density Conservation Agents; Delayed-Action Preparations; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal | 2005 |
Clinical utility of a pharmacostatistical model for ibandronate in postmenopausal osteoporosis.
Topics: Bone Density Conservation Agents; Computer Simulation; Diphosphonates; Female; Humans; Ibandronic Acid; Models, Biological; Osteoporosis, Postmenopausal | 2006 |
Compliance with treatment for osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Patient Compliance | 2006 |
Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandronic Acid; Interviews as Topic; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Patient Satisfaction; Risedronic Acid; United States | 2006 |
Use of intravenous bisphosphonates in osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Pamidronate; Patient Compliance; Zoledronic Acid | 2007 |
Osteoporosis medication profile preference: results from the PREFER-US study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Internet; Middle Aged; Osteoporosis, Postmenopausal; Patient Satisfaction; Socioeconomic Factors; Time Factors | 2007 |
Osteoporosis: non-hormonal treatment.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcitonin; Calcium, Dietary; Denosumab; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Thiophenes; Vitamin D; Women's Health | 2007 |
Ibandronic acid. BM 210955, RPR 102289A, methylpentylaminopropylidene, Bondronat Bonviva.
Topics: Animals; Diphosphonates; Dogs; Drug Interactions; Drugs, Investigational; Female; Humans; Ibandronic Acid; Osteoporosis; Osteoporosis, Postmenopausal | 1999 |